Evidence map›Paper›PMID 25394644›Full record

Trial reportReproductive sciences (Thousand Oaks, Calif.)2015

Effectiveness and Safety of Lower Doses of Mifepristone Combined With Misoprostol for the Termination of Ultra-Early Pregnancy: A Dose-Ranging Randomized Controlled Trial.

Cui-Lan Li, Dun-Jin Chen, Li-Ping Song, Yan Wang, Zhong-Fang Zhang, Ming-Xing Liu, Wei-Ling Chen

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Reproductive sciences (Thousand Oaks, Calif.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Medical methods for first trimester abortion.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cui-Lan LiThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China ninacuilanli@gmail.com.
Dun-Jin ChenThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Li-Ping SongThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Yan WangThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Zhong-Fang ZhangThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Ming-Xing LiuThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Wei-Ling ChenThe Third Affiliated Hospital of Guangzhou Medical University & Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou, China.
Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the effectiveness and safety of lower doses of mifepristone combined with misoprostol for the termination of ultra-early pregnancy. A total of 2500 women with ultra-early pregnancy (amenorrhea ≤ 35 days) were randomly divided into 5 groups with gradually decreased dose of oral mifepristone from 150 to 50 mg followed by 200 µg of oral misoprostol 24 hours later. The primary end point was complete abortion without surgical intervention. Secondary end points were vaginal bleeding, return of menses, and side effects. Rates of complete abortion were high in all groups. Moreover, the lower doses of mifepristone led to shorter vaginal bleeding period, the return of menses on the expected date, and fewer side effects. Lower doses of mifepristone combined with 200 µg of misoprostol are as effective and safe as higher doses of this combination for the termination of ultra-early pregnancy with lower possibility of vaginal bleeding and side effects.

Indexed as

Abortifacient AgentsAbortion, InducedAdministration, OralAdultChinaDose-Response Relationship, DrugDrug Therapy, CombinationFemaleHumansMifepristoneMisoprostolPregnancyPregnancy Trimester, FirstTime FactorsTreatment OutcomeYoung AdultAbortifacient AgentsMifepristoneMisoprostolearly pregnancymifepristonemisoprostolreturn of menstruationtermination

Identifiers

PMID25394644
PMCPMC4502804
OpenAlexW2090115007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.